Oct 12, 2026 · 7 min
Listen from 5:29
Listen at 5:29
Starbucks rejects Chipotle deal as Salesforce rides AI optimism
Starbucks Denies Acquiring Chipotle, Bristol Myers Falls, Salesforce
The episode connects three market moves to deeper questions about turnaround capacity, clinical-trial interpretation, and whether enterprise software can withstand AI disruption.
- 1Starbucks denied acquiring Chipotle, raising questions about whether another turnaround would stretch its strategic capacity.
- 2Bristol Myers Squibb shares fell after lung-disease trial results produced an unexpected gap between lower- and higher-dose outcomes.
- 3Bank of America’s Salesforce upgrade frames embedded data and workflows as a defense against AI-driven platform disruption.
Don't miss
The Salesforce discussion turns AI from a disruption threat into a potential advantage because companies may resist abandoning platforms containing their data and workflows.
The brief
Chipotle shares fell after Starbucks denied acquisition rumors, prompting a broader question: could Starbucks absorb another turnaround while still repairing its own business?
Matthew Griffin provides market context as the discussion weighs the strategic logic of a Starbucks-Chipotle deal and the leadership challenges surrounding both restaurant companies.
Bristol Myers Squibb became the episode’s clearest case of confusing evidence: lung-disease trial results sent shares lower because the higher-dose outcome did not behave as expected.
Salesforce rallied after Bank of America upgraded the stock, arguing that AI could strengthen rather than undermine a platform woven into large companies’ data and workflows.